Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody
Neutralizing antibody detection can assess the incidence of coronavirus disease 2019 (COVID-19) and the effectiveness of vaccines. However, commercial reagents for neutralizing antibodies were developed after the anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin (Ig)...
Gespeichert in:
| Veröffentlicht in: | Archives of pathology & laboratory medicine (1976) 2022-07, Vol.146 (7), p.814-821 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 821 |
|---|---|
| container_issue | 7 |
| container_start_page | 814 |
| container_title | Archives of pathology & laboratory medicine (1976) |
| container_volume | 146 |
| creator | Xue, Jian-Hang Wang, Yong-Jing Li, Wei Li, Qiu-Ling Xu, Qiu-Yan Niu, Jian-Jun Liu, Li-Li |
| description | Neutralizing antibody detection can assess the incidence of coronavirus disease 2019 (COVID-19) and the effectiveness of vaccines. However, commercial reagents for neutralizing antibodies were developed after the anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin (Ig) G and IgM antibodies. Therefore, some laboratories did not perform neutralizing antibody testing services due to multiple factors.
To find a fast, accurate, and economical alternative for the detection of neutralizing antibodies for the development of COVID-19 screening programs.
The response and correlation of three antibodies (anti-spike protein (S) neutralizing antibody, total anti-receptor-binding domain (RBD) antibody, and anti-RBD IgG) was determined by observing the dynamics in 61 participants for 160 days post vaccination.
The levels of neutralizing and anti-RBD IgG antibodies reached their peak values on day 42 post vaccination (120.75 IU/mL and 14.38 signal-to-cutoff ratio [S/CO], respectively). The total antibody levels peaked at 138.47 S/CO on day 35 post vaccination. The strongest correlation was found between neutralizing and anti-RBD IgG antibody levels (r = 0.894, P < .001). The area under the receiver operating characteristic curve (ROC-AUC) for total antibody levels for the prediction of seropositivity for neutralizing antibodies was 0.881 (P < .001) and that for anti-RBD IgG antibody levels was 0.937 (P < .001).
Neutralizing and anti-RBD IgG antibody levels were strongly correlated, and thus anti-RBD IgG antibody levels can be used for accurate assessment of immunity following SARS-CoV-2 infection or vaccination. |
| doi_str_mv | 10.5858/arpa.2022-0041-SA |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2647211809</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A709819699</galeid><sourcerecordid>A709819699</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-c34ba1d488f752ca9ec8d0576d802df293664a774f73a89b660c3a04cc3b92b83</originalsourceid><addsrcrecordid>eNptks1u1DAUhS0EotPCA7BBlpBQNx78kzj2MgxQKlWAGmBrOY4zdZXYg50gDTveHIe2QNHIC-tefedc--oA8IzgdSlK8UrHnV5TTCnCuCCoqR-AFSkLhijh5UOwwhgzJKUoj8BxSte5lJSSx-CIlUxgTugK_Kz95NClNXY3hYheO985v4Vvwqidh-fjOPuwHUI7D7k8gwvdhm4PdYIafoq2cybrYOhhY2PYheQm991Ne9jn7m_vpr5s0CZ8RRR-sPMU9eB-LCPurJ6AR70ekn16e5-AL-_eft68Rxcfz8439QUyJRYTMqxoNekKIfqqpEZLa0SHy4p3AtOup5JxXuiqKvqKaSFbzrFhGhfGsFbSVrATcHrju4vh22zTpEaXjB0G7W2Yk6K8qCghAsuMvvgPvQ5z9Pl1mRIFJYwR_pfa6sEq5_uQP2cWU1VXWAoiuVy80AFqa73Nmwje9i637_HrA3w-nR2dOSh4-Y_gyuphukphmCcXfLoPkhvQxJBStL3aRTfquFcEqyVPasmTWvKkljypps6a57ebmNvRdn8UdwFivwBwksQr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2684213316</pqid></control><display><type>article</type><title>Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody</title><source>Allen Press Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Xue, Jian-Hang ; Wang, Yong-Jing ; Li, Wei ; Li, Qiu-Ling ; Xu, Qiu-Yan ; Niu, Jian-Jun ; Liu, Li-Li</creator><creatorcontrib>Xue, Jian-Hang ; Wang, Yong-Jing ; Li, Wei ; Li, Qiu-Ling ; Xu, Qiu-Yan ; Niu, Jian-Jun ; Liu, Li-Li</creatorcontrib><description>Neutralizing antibody detection can assess the incidence of coronavirus disease 2019 (COVID-19) and the effectiveness of vaccines. However, commercial reagents for neutralizing antibodies were developed after the anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin (Ig) G and IgM antibodies. Therefore, some laboratories did not perform neutralizing antibody testing services due to multiple factors.
To find a fast, accurate, and economical alternative for the detection of neutralizing antibodies for the development of COVID-19 screening programs.
The response and correlation of three antibodies (anti-spike protein (S) neutralizing antibody, total anti-receptor-binding domain (RBD) antibody, and anti-RBD IgG) was determined by observing the dynamics in 61 participants for 160 days post vaccination.
The levels of neutralizing and anti-RBD IgG antibodies reached their peak values on day 42 post vaccination (120.75 IU/mL and 14.38 signal-to-cutoff ratio [S/CO], respectively). The total antibody levels peaked at 138.47 S/CO on day 35 post vaccination. The strongest correlation was found between neutralizing and anti-RBD IgG antibody levels (r = 0.894, P < .001). The area under the receiver operating characteristic curve (ROC-AUC) for total antibody levels for the prediction of seropositivity for neutralizing antibodies was 0.881 (P < .001) and that for anti-RBD IgG antibody levels was 0.937 (P < .001).
Neutralizing and anti-RBD IgG antibody levels were strongly correlated, and thus anti-RBD IgG antibody levels can be used for accurate assessment of immunity following SARS-CoV-2 infection or vaccination.</description><identifier>ISSN: 0003-9985</identifier><identifier>ISSN: 1543-2165</identifier><identifier>EISSN: 1543-2165</identifier><identifier>DOI: 10.5858/arpa.2022-0041-SA</identifier><identifier>PMID: 35380612</identifier><language>eng</language><publisher>United States: College of American Pathologists</publisher><subject>ACE2 ; Angiotensin ; Angiotensin-converting enzyme 2 ; Antibodies ; Antigens ; Blood & organ donations ; Blood donors ; Chronic illnesses ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Health aspects ; Hypersensitivity ; Immune system ; Immunoassay ; Immunoglobulin G ; Immunoglobulin M ; Immunoglobulins ; Laboratories ; Measurement ; Peptidyl-dipeptidase A ; Population studies ; Proteins ; Severe acute respiratory syndrome coronavirus 2 ; Spike protein ; Statistical analysis ; Testing ; Vaccine efficacy ; Vaccines</subject><ispartof>Archives of pathology & laboratory medicine (1976), 2022-07, Vol.146 (7), p.814-821</ispartof><rights>2022 College of American Pathologists.</rights><rights>COPYRIGHT 2022 College of American Pathologists</rights><rights>Copyright College of American Pathologists Jul 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-c34ba1d488f752ca9ec8d0576d802df293664a774f73a89b660c3a04cc3b92b83</citedby><cites>FETCH-LOGICAL-c508t-c34ba1d488f752ca9ec8d0576d802df293664a774f73a89b660c3a04cc3b92b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35380612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xue, Jian-Hang</creatorcontrib><creatorcontrib>Wang, Yong-Jing</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Li, Qiu-Ling</creatorcontrib><creatorcontrib>Xu, Qiu-Yan</creatorcontrib><creatorcontrib>Niu, Jian-Jun</creatorcontrib><creatorcontrib>Liu, Li-Li</creatorcontrib><title>Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody</title><title>Archives of pathology & laboratory medicine (1976)</title><addtitle>Arch Pathol Lab Med</addtitle><description>Neutralizing antibody detection can assess the incidence of coronavirus disease 2019 (COVID-19) and the effectiveness of vaccines. However, commercial reagents for neutralizing antibodies were developed after the anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin (Ig) G and IgM antibodies. Therefore, some laboratories did not perform neutralizing antibody testing services due to multiple factors.
To find a fast, accurate, and economical alternative for the detection of neutralizing antibodies for the development of COVID-19 screening programs.
The response and correlation of three antibodies (anti-spike protein (S) neutralizing antibody, total anti-receptor-binding domain (RBD) antibody, and anti-RBD IgG) was determined by observing the dynamics in 61 participants for 160 days post vaccination.
The levels of neutralizing and anti-RBD IgG antibodies reached their peak values on day 42 post vaccination (120.75 IU/mL and 14.38 signal-to-cutoff ratio [S/CO], respectively). The total antibody levels peaked at 138.47 S/CO on day 35 post vaccination. The strongest correlation was found between neutralizing and anti-RBD IgG antibody levels (r = 0.894, P < .001). The area under the receiver operating characteristic curve (ROC-AUC) for total antibody levels for the prediction of seropositivity for neutralizing antibodies was 0.881 (P < .001) and that for anti-RBD IgG antibody levels was 0.937 (P < .001).
Neutralizing and anti-RBD IgG antibody levels were strongly correlated, and thus anti-RBD IgG antibody levels can be used for accurate assessment of immunity following SARS-CoV-2 infection or vaccination.</description><subject>ACE2</subject><subject>Angiotensin</subject><subject>Angiotensin-converting enzyme 2</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Blood & organ donations</subject><subject>Blood donors</subject><subject>Chronic illnesses</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Health aspects</subject><subject>Hypersensitivity</subject><subject>Immune system</subject><subject>Immunoassay</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin M</subject><subject>Immunoglobulins</subject><subject>Laboratories</subject><subject>Measurement</subject><subject>Peptidyl-dipeptidase A</subject><subject>Population studies</subject><subject>Proteins</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike protein</subject><subject>Statistical analysis</subject><subject>Testing</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><issn>0003-9985</issn><issn>1543-2165</issn><issn>1543-2165</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptks1u1DAUhS0EotPCA7BBlpBQNx78kzj2MgxQKlWAGmBrOY4zdZXYg50gDTveHIe2QNHIC-tefedc--oA8IzgdSlK8UrHnV5TTCnCuCCoqR-AFSkLhijh5UOwwhgzJKUoj8BxSte5lJSSx-CIlUxgTugK_Kz95NClNXY3hYheO985v4Vvwqidh-fjOPuwHUI7D7k8gwvdhm4PdYIafoq2cybrYOhhY2PYheQm991Ne9jn7m_vpr5s0CZ8RRR-sPMU9eB-LCPurJ6AR70ekn16e5-AL-_eft68Rxcfz8439QUyJRYTMqxoNekKIfqqpEZLa0SHy4p3AtOup5JxXuiqKvqKaSFbzrFhGhfGsFbSVrATcHrju4vh22zTpEaXjB0G7W2Yk6K8qCghAsuMvvgPvQ5z9Pl1mRIFJYwR_pfa6sEq5_uQP2cWU1VXWAoiuVy80AFqa73Nmwje9i637_HrA3w-nR2dOSh4-Y_gyuphukphmCcXfLoPkhvQxJBStL3aRTfquFcEqyVPasmTWvKkljypps6a57ebmNvRdn8UdwFivwBwksQr</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Xue, Jian-Hang</creator><creator>Wang, Yong-Jing</creator><creator>Li, Wei</creator><creator>Li, Qiu-Ling</creator><creator>Xu, Qiu-Yan</creator><creator>Niu, Jian-Jun</creator><creator>Liu, Li-Li</creator><general>College of American Pathologists</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20220701</creationdate><title>Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody</title><author>Xue, Jian-Hang ; Wang, Yong-Jing ; Li, Wei ; Li, Qiu-Ling ; Xu, Qiu-Yan ; Niu, Jian-Jun ; Liu, Li-Li</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-c34ba1d488f752ca9ec8d0576d802df293664a774f73a89b660c3a04cc3b92b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>ACE2</topic><topic>Angiotensin</topic><topic>Angiotensin-converting enzyme 2</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Blood & organ donations</topic><topic>Blood donors</topic><topic>Chronic illnesses</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Health aspects</topic><topic>Hypersensitivity</topic><topic>Immune system</topic><topic>Immunoassay</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin M</topic><topic>Immunoglobulins</topic><topic>Laboratories</topic><topic>Measurement</topic><topic>Peptidyl-dipeptidase A</topic><topic>Population studies</topic><topic>Proteins</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike protein</topic><topic>Statistical analysis</topic><topic>Testing</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xue, Jian-Hang</creatorcontrib><creatorcontrib>Wang, Yong-Jing</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Li, Qiu-Ling</creatorcontrib><creatorcontrib>Xu, Qiu-Yan</creatorcontrib><creatorcontrib>Niu, Jian-Jun</creatorcontrib><creatorcontrib>Liu, Li-Li</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of pathology & laboratory medicine (1976)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xue, Jian-Hang</au><au>Wang, Yong-Jing</au><au>Li, Wei</au><au>Li, Qiu-Ling</au><au>Xu, Qiu-Yan</au><au>Niu, Jian-Jun</au><au>Liu, Li-Li</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody</atitle><jtitle>Archives of pathology & laboratory medicine (1976)</jtitle><addtitle>Arch Pathol Lab Med</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>146</volume><issue>7</issue><spage>814</spage><epage>821</epage><pages>814-821</pages><issn>0003-9985</issn><issn>1543-2165</issn><eissn>1543-2165</eissn><abstract>Neutralizing antibody detection can assess the incidence of coronavirus disease 2019 (COVID-19) and the effectiveness of vaccines. However, commercial reagents for neutralizing antibodies were developed after the anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin (Ig) G and IgM antibodies. Therefore, some laboratories did not perform neutralizing antibody testing services due to multiple factors.
To find a fast, accurate, and economical alternative for the detection of neutralizing antibodies for the development of COVID-19 screening programs.
The response and correlation of three antibodies (anti-spike protein (S) neutralizing antibody, total anti-receptor-binding domain (RBD) antibody, and anti-RBD IgG) was determined by observing the dynamics in 61 participants for 160 days post vaccination.
The levels of neutralizing and anti-RBD IgG antibodies reached their peak values on day 42 post vaccination (120.75 IU/mL and 14.38 signal-to-cutoff ratio [S/CO], respectively). The total antibody levels peaked at 138.47 S/CO on day 35 post vaccination. The strongest correlation was found between neutralizing and anti-RBD IgG antibody levels (r = 0.894, P < .001). The area under the receiver operating characteristic curve (ROC-AUC) for total antibody levels for the prediction of seropositivity for neutralizing antibodies was 0.881 (P < .001) and that for anti-RBD IgG antibody levels was 0.937 (P < .001).
Neutralizing and anti-RBD IgG antibody levels were strongly correlated, and thus anti-RBD IgG antibody levels can be used for accurate assessment of immunity following SARS-CoV-2 infection or vaccination.</abstract><cop>United States</cop><pub>College of American Pathologists</pub><pmid>35380612</pmid><doi>10.5858/arpa.2022-0041-SA</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-9985 |
| ispartof | Archives of pathology & laboratory medicine (1976), 2022-07, Vol.146 (7), p.814-821 |
| issn | 0003-9985 1543-2165 1543-2165 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2647211809 |
| source | Allen Press Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | ACE2 Angiotensin Angiotensin-converting enzyme 2 Antibodies Antigens Blood & organ donations Blood donors Chronic illnesses Coronaviruses COVID-19 COVID-19 vaccines Health aspects Hypersensitivity Immune system Immunoassay Immunoglobulin G Immunoglobulin M Immunoglobulins Laboratories Measurement Peptidyl-dipeptidase A Population studies Proteins Severe acute respiratory syndrome coronavirus 2 Spike protein Statistical analysis Testing Vaccine efficacy Vaccines |
| title | Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T07%3A14%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-Receptor-Binding%20Domain%20Immunoglobulin%20G%20Antibody%20as%20a%20Predictor%20of%20Seropositivity%20for%20Anti-SARS-CoV-2%20Neutralizing%20Antibody&rft.jtitle=Archives%20of%20pathology%20&%20laboratory%20medicine%20(1976)&rft.au=Xue,%20Jian-Hang&rft.date=2022-07-01&rft.volume=146&rft.issue=7&rft.spage=814&rft.epage=821&rft.pages=814-821&rft.issn=0003-9985&rft.eissn=1543-2165&rft_id=info:doi/10.5858/arpa.2022-0041-SA&rft_dat=%3Cgale_proqu%3EA709819699%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2684213316&rft_id=info:pmid/35380612&rft_galeid=A709819699&rfr_iscdi=true |